Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin-Reference-Cited by-同舟云学术

Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin

Published:2023-09-11 Issue:1 Volume:76 Page:49-89
ISSN:0031-6997
Container-title:Pharmacological Reviews
language:en
Short-container-title:Pharmacol Rev

Author:

Gogate Anagha,Belcourt Jordyn,Shah Milan,Wang Alicia Zongxun,Frankel Alexis,Kolmel Holly,Chalon Matthew,Stephen Prajith,Kolli Aarush,Tawfik Sherouk M.,Jin Jing^ORCID,Bahal Raman,Rasmussen Theodore P.,Manautou José E.,Zhong Xiao-bo^ORCID

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference308 articles.

1. RNAi therapeutics: Principles, prospects and challenges

2. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

3. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

4. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

5. A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studies;Ahn;CPT Pharmacometrics Syst Pharmacol,2023

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice;Journal of Thrombosis and Thrombolysis;2024-09-02

2. Current status and trends in small nucleic acid drug development: Leading the future;Acta Pharmaceutica Sinica B;2024-09

3. Oral Piwi‐Interacting RNA Delivery Mediated by Green Tea‐Derived Exosome‐Like Nanovesicles for the Treatment of Aortic Dissection;Advanced Healthcare Materials;2024-08

4. The Growing Class of Novel RNAi Therapeutics;Molecular Pharmacology;2024-05-06

5. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction–associated steatohepatitis;Journal of Clinical Investigation;2024-04-01